Cargando…

Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia

Trabectedin (ET743) and lurbinectedin (PM01183) limit the production of inflammatory cytokines that are elevated during cancer cachexia. Mice carrying C26 colon adenocarcinoma display cachexia (i.e., premature death and body wasting with muscle, fat and cardiac tissue depletion), high levels of infl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aquila, Giorgio, Re Cecconi, Andrea David, Forti, Mara, Frapolli, Roberta, Bello, Ezia, Novelli, Deborah, Russo, Ilaria, Licandro, Simonetta Andrea, Staszewsky, Lidia, Martinelli, Giulia Benedetta, Talamini, Laura, Pasetto, Laura, Resovi, Andrea, Giavazzi, Raffaella, Scanziani, Eugenio, Careccia, Giorgia, Vénéreau, Emilie, Masson, Serge, Latini, Roberto, D’Incalci, Maurizio, Piccirillo, Rosanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463843/ https://www.ncbi.nlm.nih.gov/pubmed/32824440 http://dx.doi.org/10.3390/cancers12082312

Ejemplares similares

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022)

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives
por: Zambelli, Alberto, et al.
Publicado: (2023)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

New activities for the anti-tumor agent trabectedin: taking two birds with one stone
por: D'Incalci, Maurizio, et al.
Publicado: (2013)

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2019)

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
por: Romano, Michela, et al.
Publicado: (2017)

Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2020)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

Inhibition of tumor‐associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti‐PD‐1 therapy
por: Belgiovine, Cristina, et al.
Publicado: (2021)

Specific Effects of Trabectedin and Lurbinectedin on Human Macrophage Function and Fate—Novel Insights
por: Povo-Retana, Adrián, et al.
Publicado: (2020)

Immunometabolic actions of trabectedin and lurbinectedin on human macrophages: relevance for their anti-tumor activity
por: Povo-Retana, Adrián, et al.
Publicado: (2023)

Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
por: Galmarini, Carlos M., et al.
Publicado: (2014)

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
por: D'Incalci, M, et al.
Publicado: (2014)

Trabectedin: A drug from the sea that strikes tumor-associated macrophages
por: Allavena, Paola, et al.
Publicado: (2013)

Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging
por: Giordano, Silvia, et al.
Publicado: (2016)

Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB
por: Camorani, Simona, et al.
Publicado: (2018)

Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair
por: Lima, Michelle, et al.
Publicado: (2016)

HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance
por: Loria, Rossella, et al.
Publicado: (2018)

Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma
por: Gadducci, Angiolo, et al.
Publicado: (2022)

Mechanism of action of trabectedin in desmoplastic small round cell tumor cells
por: Uboldi, S., et al.
Publicado: (2017)

Lurbinectedin in small cell lung cancer
por: Manzo, Anna, et al.
Publicado: (2022)

Nutraceuticals and Exercise against Muscle Wasting during Cancer Cachexia
por: Aquila, Giorgio, et al.
Publicado: (2020)

A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia
por: Mannarino, L, et al.
Publicado: (2018)

3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors
por: Giordano, S., et al.
Publicado: (2016)

Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts.
por: Giavazzi, R., et al.
Publicado: (1988)

A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin
por: Grosso, Federica, et al.
Publicado: (2012)

Determination of Paclitaxel Distribution in Solid Tumors by Nano-Particle Assisted Laser Desorption Ionization Mass Spectrometry Imaging
por: Morosi, Lavinia, et al.
Publicado: (2013)

Characterization of the Cardiac Structure and Function of Conscious D2.B10-Dmd(mdx)/J (D2-mdx) mice from 16–17 to 24–25 Weeks of Age
por: De Giorgio, Daria, et al.
Publicado: (2023)

Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle
por: Pretto, Francesca, et al.
Publicado: (2014)

Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity
por: Herzog, J., et al.
Publicado: (2016)

Correction: Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle
por: Pretto, Francesca, et al.
Publicado: (2016)

A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging
por: Giordano, Silvia, et al.
Publicado: (2017)

Apelin Resistance Contributes to Muscle Loss during Cancer Cachexia in Mice
por: Re Cecconi, Andrea David, et al.
Publicado: (2022)

A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma
por: Uboldi, Sarah, et al.
Publicado: (2012)

Lurbinectedin for small cell lung cancer
Publicado: (2021)

Oxidation of HMGB1 Is a Dynamically Regulated Process in Physiological and Pathological Conditions
por: Ferrara, Michele, et al.
Publicado: (2020)

Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells
por: Russo, Massimo, et al.
Publicado: (2023)

Lurbinectedin-induced thrombocytopenia: the role of body surface area
por: Papachristos, Apostolos, et al.
Publicado: (2022)

Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma
por: Anobile, Dario P., et al.
Publicado: (2021)

A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma
por: Gadducci, Angiolo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_va3hggq9s4vgs9gbhgdam55gck